Cytotoxicity of myeloperoxidase-activated catechols: oxidative injury to the red blood cell

Zyl, Johann M. van; Basson, Karen; Kriegler, A.; Walt, B. J. Van Der

doi:10.1016/0300-483x(91)90060-e

Cited by 5 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[36] However, in two other studies, this was not confirmed. [44][45][46][47][48][49][50][51] A more recent study has shown that the anti-inflammatory action of dapsone is via inhibition of calcium-dependent functions of neutrophils, including release of tissue-damaging oxidants and proteases in the affected skin. [40] The analysis of the data demonstrated that 32 of 37 (86%) patients with pemphigus vulgaris [7][8][9][10][11][12][13][14][15][16][17][18][19] and 14 of 18 (78%) patients with pemphigus foliaceus [8,[20][21][22][23][24][25][26][27][28] responded to dapsone.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Dapsone in the Treatment of Pemphigus and Pemphigoid

Gürcan

Ahmed

2009

American Journal of Clinical Dermatology

View full text Add to dashboard Cite

Dapsone is a chemotherapeutic agent primarily used in treating leprosy, Pneumocystis jiroveci (previously carinii) pneumonia, and malaria. It is also used as an adjuvant in the treatment of pemphigus and pemphigoid. To assess the role of dapsone in the treatment of pemphigus and pemphigoid, a retrospective review of reports in the English-language literature was conducted. Information on the number of patients treated, their average age, prior therapies, indications for use, protocol (dose and interval) used, concomitant therapies, reported adverse effects, and clinical outcomes were analyzed. There were 35 case reports/series published describing the use of dapsone in a total of 427 patients. Data on 55 pemphigus patients were obtained from several case reports and some case series and one randomized controlled trial. Of these, 32 patients with pemphigus vulgaris and 14 patients with pemphigus foliaceus responded to dapsone. Data from 13 case series, each including at least five patients, accounted for 372 patients with pemphigoid. The overall response rates to dapsone, when given either alone or in combination with corticosteroids or immunosuppressive agents, were 84% in mucous membrane pemphigoid, and 81% in bullous pemphigoid. Hemolysis was the most common adverse effect observed. Dapsone is a promising and useful agent in patients with autoimmune mucocutaneous blistering diseases, especially in mucous membrane pemphigoid. It can be used as a corticosteroid-sparing agent. Therefore, its combined use with oral corticosteroids may be useful in pemphigus vulgaris and bullous pemphigoid. Adverse effects of dapsone are dose dependent and usually reversible. Hemolysis and concomitant anemia secondary to hemolysis are expected in most patients. In the opinion of the authors, dapsone is underutilized in the treatment of autoimmune mucocutaneous blistering diseases.

show abstract